Want to see TSE:BIOV full AI Analyst Report?
BioVaxys Technology (BIOV) Stock Statistics & Valuation Metrics
Total Valuation
BioVaxys Technology has a market cap or net worth of CAD 2.04M. The enterprise value is CAD 5.96M.
- Market Cap
- CAD 2.04M
- Enterprise Value
- CAD 5.96M
Share Statistics
BioVaxys Technology has 44,094,670 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 44,094,670
- Owned by Insiders
- 8.08%
- Owned by Institutions
- ―
Financial Efficiency
BioVaxys Technology’s return on equity (ROE) is 2.06 and return on invested capital (ROIC) is 177.94%.
- Return on Equity (ROE)
- 2.06
- Return on Assets (ROA)
- -3.04
- Return on Invested Capital (ROIC)
- 177.94%
- Return on Capital Employed (ROCE)
- 1.72
- Revenue Per Employee
- 0
- Profits Per Employee
- -1.32M
- Employee Count
- 3
- Asset Turnover
- 0.00
- Inventory Turnover
- 0.00
Valuation Ratios
The current PE Ratio of BioVaxys Technology is -0.91. BioVaxys Technology’s PEG ratio is 0.04.
- PE Ratio
- -0.91
- PS Ratio
- 0.00
- PB Ratio
- -0.56
- Price to FCF
- -1.92
- Price to Operating Cash Flow
- -1.92
- PEG Ratio
- 0.04
Income Statement
In the last 12 months, BioVaxys Technology had revenue of 0 and earned -3.95M in profits. Earnings per share was -0.20.
- Revenue
- 0
- Gross Profit
- 0
- Operating Income
- -3.30M
- Pretax Income
- -3.95M
- Net Income
- -3.95M
- EBITDA
- -3.95M
- Earnings Per Share (EPS)
- -0.20
Cash Flow
In the last 12 months, operating cash flow was -2.97M and capital expenditures -4, giving a free cash flow of -2.97M billion.
- Operating Cash Flow
- -2.97M
- Free Cash Flow
- -2.97M
- Free Cash Flow per Share
- -0.04
Dividends & Yields
BioVaxys Technology pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -52.18%
- Earnings Yield
- -109.12%
Stock Price Statistics
- Beta
- 1.36
- 52-Week Price Change
- -74.55%
- 50-Day Moving Average
- 0.07
- 200-Day Moving Average
- 0.08
- Relative Strength Index (RSI)
- 54.04
- Average Volume (3m)
- ―
Important Dates
BioVaxys Technology upcoming earnings date is Apr 01, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Sep 25, 2026
- Next Earnings Date
- Apr 01, 2027
- Ex-Dividend Date
- ―
Financial Position
BioVaxys Technology as a current ratio of 0.40, with Debt / Equity ratio of -3.55%
- Current Ratio
- 0.40
- Quick Ratio
- 0.40
- Debt to Market Cap
- 0.00
- Net Debt to EBITDA
- 0.04
- Interest Coverage Ratio
- 0.00
Taxes
In the past 12 months, BioVaxys Technology has paid 0 in taxes.
- Income Tax
- 0
- Effective Tax Rate
- 0.00
Enterprise Valuation
BioVaxys Technology EV to EBITDA ratio is -1.68, with an EV/FCF ratio of -2.04.
- EV to Sales
- 0.00
- EV to EBITDA
- -1.68
- EV to Free Cash Flow
- -2.04
- EV to Operating Cash Flow
- -2.04
Balance Sheet
BioVaxys Technology has CAD 4,080.00 in cash and marketable securities with CAD 133.72K in debt, giving a net cash position of -CAD 129.64K billion.
- Cash & Marketable Securities
- CAD 4,080.00
- Total Debt
- CAD 133.72K
- Net Cash
- -CAD 129.64K
- Net Cash Per Share
- CAD 0.00
- Tangible Book Value Per Share
- -CAD 0.12
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
- Gross Margin
- 0.00%
- Operating Margin
- 0.00%
- Pretax Margin
- 0.00%
- Net Profit Margin
- 0.00%
- EBITDA Margin
- 0.00%
- EBIT Margin
- 0.00%
Scores
- Smart Score
- ―
- AI Score
- 28.5